Journal of Medicinal Chemistry p. 320 - 330 (1993)
Update date:2022-09-26
Topics:
Kempf, Dale J.
Codacovi, Lynnmarie
Wang, Xiu Chun
Kohlbrenner, William E.
Wideburg, Norman E.
et al.
The structure-activity relationships in two series of novel, symmetry-based inhibitors of HIV protease, the enzyme responsible for maturation of the human immunodeficiency virus, are described.Beginning with lead compounds 3-6, the effect of adding polar, heterocyclic end groups to one or both ends of the symmetric or pseudosymmetric inhibitors was probed.Aqueous solubility was enhanced >1000-fold while maintaining potent inhibition of purified HIV-1 protease and anti-HIV activity in vitro.Pharmacokinetic studies in rats indicated a substantial difference in the absorption properties of mono-ol-based and diol-based inhibitors.The oral bioavailability of inhibitor 19 in rats was 19percent; however, the Cmax obtained failed to exceed the anti-HIV EC50 in vitro.Substantial plasma levels of potent inhibitors of the diol class were not obtained after oral administration in rats; however, the optimal combination of aqueous solubility and in vitro antiviral activity of several inhibitors support their potential use in intravenous therapy.
View MoreShanghai Xinda Pharmaceuticals Co., Ltd.
Contact:86-21-33692333-8008
Address:999 Linxian Road, Jinshan Industrial Park, Shanghai, China
Nanjing Chemzam Pharmtech Co., Ltd.
Contact:+86-25-86462165,+86-13915979898
Address:C5-1,6 Maiyue Road,Maigaoqiao,Nanjing,Jiangsu,China
Contact:086-027-83820093
Address:16#luojiashan, wuchang district
Contact:86-311-67265101
Address:203 Lianmeng Road, Qiaoxi District
FUJIAN SHANSHUI CHEMICAL CORP.LTD.
Contact:+86-151-59920036
Address:Jinqiao Gareden, jo@fj-xinyi.com
Doi:10.1016/0223-5234(96)88246-8
(1995)Doi:10.1021/ml300262e
(2013)Doi:10.1021/jo00307a027
(1990)Doi:10.1021/jm301597s
(2012)Doi:10.1080/00397911.2011.602498
(2013)Doi:10.1016/j.ejmech.2012.09.031
(2012)